Tenofivir disoproxil (Dolamvir)
Tenofivir disoproxil
Novagen Pharma (Pty) Ltd
Registration
- Applicant
- Novagen Pharma (Pty) Ltd
- Certificate holder
- Novagen Pharma (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Dolamvir EACH TABLET CONTAINS DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE EQUIVALENT TO TENOFIVIR DISOPROXIL 245,0 mg | 50 mg, 300 mg, 300 mg,Tablets | 56034256/20.2.8/0342Approved 10 October 2023 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.